These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 38492132)

  • 1. Prophylaxis of hepatic encephalopathy: current and future drug targets.
    Maharshi S; Sharma BC
    Hepatol Int; 2024 Aug; 18(4):1096-1109. PubMed ID: 38492132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the Therapeutic Management of Hepatic Encephalopathy.
    Kornerup LS; Gluud LL; Vilstrup H; Dam G
    Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
    Alsahhar JS; Rahimi RS
    Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Management of Hepatic Encephalopathy.
    Mahpour NY; Pioppo-Phelan L; Reja M; Tawadros A; Rustgi VK
    Clin Liver Dis; 2020 May; 24(2):231-242. PubMed ID: 32245530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
    Goh ET; Stokes CS; Sidhu SS; Vilstrup H; Gluud LL; Morgan MY
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012410. PubMed ID: 29762873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic Management of Hepatic Encephalopathy.
    Khalessi A; Pyrsopoulos NT
    Clin Liver Dis; 2024 May; 28(2):287-296. PubMed ID: 38548440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Overt Hepatic Encephalopathy.
    Sussman NL
    Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
    Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
    Henderson PK; Herrera JL
    Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands.
    de Jong LA; van Schoonhoven AV; Hofstra HS; Postma MJ; van Hoek B
    J Med Econ; 2021; 24(1):1149-1163. PubMed ID: 34629016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.